Steven M Albert1, June R Lunney2, Lei Ye3, Robert Boudreau3, Diane Ives3, Suzanne Satterfield4, Hilsa N Ayonayon5, Susan M Rubin5, Anne B Newman3, Tamara Harris6. 1. Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Electronic address: smalbert@pitt.edu. 2. Hospital and Palliative Nursing Association, Pittsburgh, Pennsylvania, USA. 3. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 4. Department of Preventive Medicine, University of Tennessee, Memphis, Tennessee, USA. 5. Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California, USA. 6. Laboratory of Epidemiology, Biometry, and Demography, National Institute on Aging, Bethesda, Maryland, USA.
Abstract
CONTEXT: End-of-life (EOL) treatment preferences among the very old (age 85+) may differ from preferences in younger aged populations because of high levels of symptom burden and disability and high risk of mortality. It is unclear if symptom burden or level of disability is more important for such preferences. OBJECTIVES: To investigate whether distress from daily symptom burden was an independent correlate of EOL treatment preferences over two years of follow-up in people with median age 86 (participants) and 88 (reported by proxies) at baseline. METHODS: The End of Life in Very Old Age is an ancillary study to the Health, Aging and Body Composition study. At baseline in Year 15 of Health, Aging and Body Composition, 1038 participants and 189 proxies reported levels of symptom distress every quarter, as well as 0-8 EOL treatment preferences elicited once each year. RESULTS: At baseline, the mean (SD) count of EOL treatment preferences was 4.2 (2.1) in participants, and 2.9 (2.3) in proxies. EOL treatment preference was not associated with symptom distress. By contrast, black race, male gender, and reported ease walking a quarter mile were independently associated with more aggressive EOL treatment preferences. CONCLUSION: Preferences for more aggressive EOL treatment were not related to daily symptom distress but were significantly more likely to be endorsed among those with better mobility, suggesting that disability is an independent predictor of EOL treatment preferences in the very old.
CONTEXT: End-of-life (EOL) treatment preferences among the very old (age 85+) may differ from preferences in younger aged populations because of high levels of symptom burden and disability and high risk of mortality. It is unclear if symptom burden or level of disability is more important for such preferences. OBJECTIVES: To investigate whether distress from daily symptom burden was an independent correlate of EOL treatment preferences over two years of follow-up in people with median age 86 (participants) and 88 (reported by proxies) at baseline. METHODS: The End of Life in Very Old Age is an ancillary study to the Health, Aging and Body Composition study. At baseline in Year 15 of Health, Aging and Body Composition, 1038 participants and 189 proxies reported levels of symptom distress every quarter, as well as 0-8 EOL treatment preferences elicited once each year. RESULTS: At baseline, the mean (SD) count of EOL treatment preferences was 4.2 (2.1) in participants, and 2.9 (2.3) in proxies. EOL treatment preference was not associated with symptom distress. By contrast, black race, male gender, and reported ease walking a quarter mile were independently associated with more aggressive EOL treatment preferences. CONCLUSION: Preferences for more aggressive EOL treatment were not related to daily symptom distress but were significantly more likely to be endorsed among those with better mobility, suggesting that disability is an independent predictor of EOL treatment preferences in the very old.
Authors: M B Hamel; R B Davis; J M Teno; W A Knaus; J Lynn; F Harrell; A N Galanos; A W Wu; R S Phillips Journal: Ann Intern Med Date: 1999-11-16 Impact factor: 25.391
Authors: Michelle Y Martin; Maria Pisu; Robert A Oster; Julie M Urmie; Deborah Schrag; Haiden A Huskamp; Jeannette Lee; Catarina I Kiefe; Mona N Fouad Journal: Cancer Date: 2011-04-26 Impact factor: 6.860
Authors: Susan L Mitchell; Joan M Teno; Dan K Kiely; Michele L Shaffer; Richard N Jones; Holly G Prigerson; Ladislav Volicer; Jane L Givens; Mary Beth Hamel Journal: N Engl J Med Date: 2009-10-15 Impact factor: 91.245
Authors: Joseph B Straton; Nae-Yuh Wang; Lucy A Meoni; Daniel E Ford; Michael J Klag; David Casarett; Joseph J Gallo Journal: J Am Geriatr Soc Date: 2004-04 Impact factor: 5.562
Authors: Allison B Brenner; Lesli E Skolarus; Chithra R Perumalswami; James F Burke Journal: J Pain Symptom Manage Date: 2020-05-04 Impact factor: 3.612